Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


West Nile assay

This article was originally published in The Gray Sheet

Executive Summary

Chiron and Gen-Probe expect to file with FDA in early 2005 for their jointly developed West Nile virus blood donation screening assay for the Procleix Tigris automated nucleic acid testing system. The firms announced launch of an IND trial for the assay Sept. 1. The system will be tested in epidemic areas in Arizona, California, Colorado, Florida and Oklahoma to "improve the efficiency of high volume testing," they say (1"The Gray Sheet" Aug. 4, 2003, p. 21)...

You may also be interested in...

Gen-Probe Relying On Tigris To Boost Overseas Blood Screen Market Share

Gen-Probe projects a U.S. market launch in the first half of 2004 for its Tigris DTS fully automated, high-throughput molecular diagnostic instrument system

COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers

First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.

Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says

Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts